Search

everythinglearnresearchcommunity

for

Search:↓

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Ritlecitinib is effective for long-term treatment of severe alopecia areata.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Baricitinib was effective in treating both early and late onset alopecia areata.

Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.

Triptolide effectively and safely reduces actinic keratosis lesions in mice.

Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Combining ATRA with TPO-RA effectively stabilizes platelet counts in ITP patients.

Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.

Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

ATP helps prevent skin damage from vandetanib by reducing stress.

Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

A patient with complete hair loss regrew all her hair using tofacitinib.

Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.

Topical tofacitinib is effective and safe for treating alopecia areata.

Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.

Patients on dabrafenib and trametinib for melanoma often experience skin side effects.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

Oral baricitinib is effective and safe for treating alopecia areata.

Acitretin effectively prevented skin cancer in a patient with late-onset Rothmund-Thomson syndrome.

Baricitinib significantly improves hair regrowth in severe alopecia areata.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.